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select attributes in order to construct the final list of attributes. This study aims to
test the feasibility of using the nominal group technique (NGT) to select attributes
for DCEs. METHODS: Patients group discussions (4-8 participants) were conducted
in Belgium and the Netherlands to prioritize a list of twelve potentially important
attributes for osteoporosis drug therapy that were retrieved from literature review
and expert discussions. The NGT consisted of three steps: 1) an individual ranking
of the twelve attributes by importance from 1 to 12; 2) a group discussion on each of
the attributes including a group review of the aggregate score of the initial rank-
ings; and 3) a second ranking task of the same attributes. The selection of attributes
for the DCE was based on groups’ ranking and NGT discussions followed by experts’
discussion. RESULTS: In total, 26 osteoporotic patients participated in five nominal
group sessions. Most (80%) patients changed their ranking after the discussion.
However, the average initial and final ranking did not markedly differ, with two
exceptions. In the final rank, the most important medication attributes were effec-
tiveness, side-effects, frequency and mode of administration. It was also observed
that some (15%) patients did not correctly rank from 1 to 12, and the order of
attributes did play a role in the ranking. CONCLUSIONS: The nominal group tech-
nique is feasible and useful for selecting attributes for DCE, although the ranking
task may be cognitively difficult and attributes order should vary over different
NGT sessions.
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OBJECTIVES: To assess the factors that most predicts diabetic patients’ self-effi-
cacy toward osteoporosis with respect to dietary calcium and physical exercise
activity. METHODS: A cross sectional study was undertaken in 250 diabetic type 2
outpatients (T2DM) over a 3-month period in 2011. A pre-validated questionnaire
was administered to assess osteoporosis knowledge tool (OKT-M, two subscale:
exercise and calcium), osteoporosis health behaviour scale (OHBS-M, seven sub-
scales: perceived susceptibility, perceived seriousness, barriers to calcium intake,
barriers to exercise, benefits of calcium intake, benefits of exercise, and health
motivation), osteoporosis risk factor and other demographic questionnaires prior
to the Malaysian osteoporosis self-efficacy scale (OSES-M, two subscale: calcium
and exercise). Then differences, correlations and multiple regressions were exam-
ined in relation to the demographic data, OKT-M and OHBS-M. RESULTS: There
were significant differences in the independent variables: education and income in
relation to OSES-M total scores. Correlations were performed to determine the
relationship between the two dependent variables (OSES-M calcium and exercise
subscale) and the OKT-M and OHBS-M. The OKT-M calcium and exercise subscale,
health motivation and perceived benefits for exercise were positively correlated
with both OSES-M exercise and calcium intake. While perceived benefits for cal-
cium intake was positively correlated with OSES-M exercise only. Perceived barrier
for calcium intake was negatively correlated with self-efficacy for exercise and
calcium. Regression analysis revealed that knowledge, health belief and some de-
mographic data had an impact on OSES-M and the R2scores value were 0.260 and
0.309 for calcium and exercise self-efficacy, respectively. CONCLUSIONS: The pres-
ent study findings suggested that assessing factors affecting the self-efficacy be-
haviour related to bone loss in diabetic patients will raised the potential impor-
tance of these components in the overall understanding of other diabetic
complications and for development of early screening and prevention of osteopo-
rosis in T2DM patients.
PMS64
COMPARATIVE EFFICACY OF TOCILIZUMAB AND ATNF BIOLOGIC
MONOTHERAPIES ON PATIENT REPORTED OUTCOMES (PROS) IN RA PATIENTS
WHO HAVE SHOWN AN INADEQUATE RESPONSE TO CONVENTIONAL DMARDS
(DMARD-IR): A NETWORK META-ANALYSIS
Buckley F1, Ogale S2, Dejonckheere F3, Jansen JP1
1MAPI Consultancy, Boston, MA, USA, 2Genentech, South San Francisco, CA, USA,
3F. Hoffmann-La Roche Ltd., Basel, Switzerland
OBJECTIVES: Head to head data from randomized controlled trials (RCTs) compar-
ing biologic monotherapies is limited. Our objective was to compare PROs for to-
cilizumab monotherapy vs. other approved biologic monotherapies, in DMARD-IR
RA patients, based on currently available RCT evidence. METHODS: Full-text pub-
lications of RCTs that assessed tocilizumab, and other biologic therapies, as mono-
therapy in DMARD-IR patients were identified through a systematic literature re-
view. RCTs reporting data on PROs (Health Assessment Questionnaire Disability
Index (HAQ-DI), pain VAS, patient global assessment of disease activity (PGA) VAS,
SF-36, or fatigue) at 24 weeks were included. Where sufficient data was available,
Bayesian network meta-analyses was used to obtain treatment effect estimates
between included interventions. It was assumed that the effects of the aTNF treat-
ments were exchangeable, and data for the assessed aTNFs were pooled to give a
single, more stable estimate. RESULTS: Four studies were identified that formed a
network comparing monotherapy treatments (tocilizumab and aTNFs (adali-
mumab, etanercept, certolizumab pegol)) and reported PRO data. Data on pain VAS,
PGA VAS, and HAQ-DI was most commonly reported. Tocilizumab monotherapy
showed greater improvement in pain [Difference -11.38 (95% CrI -18.40, -4.32)] and
PGA [Difference -10.49 (95% CrI -17.68, -3.24)] compared to the assessed aTNF
monotherapies. Tocilizumab monotherapy showed greater improvement in
HAQ-DI [Difference -0.52 (95% CrI -0.73, -0.31)] compared with placebo, and was at
least as efficacious compared to aTNF monotherapy [Difference -0.16 (95% CrI -0.33,
0.01)]. Insufficient data was reported for the SF-36 and fatigue to allow network
meta-analysis.CONCLUSIONS: Based on network meta-analysis of currently avail-
able RCT evidence, involving indirect comparison of trial findings, tocilizumab
monotherapy was found to have better outcomes than assessed aTNF monothera-
pies in terms of patient reported pain and disease activity in a DMARD-IR RA
population. Tocilizumab was at least as efficacious as aTNF agents in improvement
in physical function.
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OBJECTIVES: To validate and determine the discriminative power of the
FibroDetect®screening tool in helping primary care physicians detect patients with
fibromyalgia in routine practice.METHODS: The FibroDetect included 14 questions
assessing patients’ pain and fatigue, personal history and attitudes, symptoms and
impact on lives. To discriminate between American College of Rheumatology pos-
itive (ACR) patients and ACR negative (ACR-) patients (n276), a scoring method
was created using an iterative process based on statistical and clinical consider-
ations. The discriminant model was then validated with fibromyalgia and non-
fibromyalgia patients (n312). A score threshold for individual ACR classification
was defined. RESULTS:Of the 14 original FibroDetect questions, six questions were
retained in the final scoring, demonstrating discriminative power between ACR
and ACR- patients with an area under the ROC curve of 0.74. A majority of ACR
patients (77%) and less than half of ACR– (39%) had a score  6, suggesting that
patients with such score are likely to be ACR, and should thus be referred to a
fibromyalgia specialist. A total of 8% of ACR patients and 79% of ACR– patients
had a score 3, suggesting that patients with such score were unlikely to be ACR,
and should thus be not be referred to a fibromyalgia specialist. Patients with a
FibroDetect score of 4 or 5 would require further investigation. The predictive ac-
curacy of the tool increased to 0.86 for fibromyalgia and non-fibromyalgia patient
detection. With a 6-point cut-off, the sensitivity was 90% and the specificity was
67% for fibromyalgia and non-fibromyalgia patient detection. CONCLUSIONS: The
FibroDetect is a screening tool that detects potential fibromyalgia patients among
patients with chronic widespread pain. It can be used as a surrogate for ACR clas-
sification criteria in primary care settings, and improve referral to appropriate
specialist.
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OBJECTIVES: Myotonic dystrophy type-1 (DM1) is a dominantly inherited disorder
caused by an unstable CTG repeat expansion on chromosome 19. Clinically the
disease is associated with a wide variety of symptoms. The Myotonic Dystrophy
Health Index (MDHI) is a disease-specific patient reported outcome measure de-
signed to measure total health, and 17 of the most important areas of disease-
specific health in DM1. The items in this instrument were selected utilizing quali-
tative interviews and a cross-sectional study of 278 patients. The MDHI’s total score
(and each of the 17 subscales) are scored from 0-100 with 100 representing the
highest level of disease. The objective of this research is to evaluate the MDHI’s
ability to differentiate between known groups of DM1 patients. METHODS: Each of
the MDHI’s 17 subscales was completed by a group of DM1 patients. DM1 respon-
dents were divided into known groups by employment status, CTG repeat number
(300,300), education (non-college graduate, college graduate), age (21-46,47
years), and duration of symptoms (21,21 years). The average subscale score and
total MDHI score was calculated for each known group. RESULTS: On average, 138
DM1 patients completed each subscale. The MDHI measured a higher disease bur-
den in patients who were unemployed (MDHI total score: 41.5 vs. 25.0), less edu-
cated (41.4 vs. 33.8), had a longer duration of symptoms (41.3 vs. 34.6), were of older
age (38.3 vs. 33.1) and those with a longer CTG repeat number (35.6 vs. 27.6).
CONCLUSIONS: The MDHI and its subscales are capable of differentiating between
known groups of DM1 patients who are suspected of having a higher burden of
disease.
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OBJECTIVES: The current analysis evaluates the long-term impacts on household
productivity and social participation of CZP 400mg Q4W combination and mono-
therapy over 5 years. METHODS: In this open-label extension (OLE) (NCT00160693)
patients (pts) originally enrolled in FAST4WARD (NCT00548834) or study 014
(NCT00544154) received CZP 400 mg Q4W for 24 wks. Pts who completed or with-
drew on/after Wk12 in either study were eligible and were permitted to take
DMARDs in OLE. Household productivity and social participation were assessed
through the RA-specific Work Productivity Survey (WPS-RA); results are reported
up to Wk268 (5.2yrs). The analyzed population consisted of (1) Wk 24 CZP com-
pleters from FAST4WARD (N75) or 014 (N96) who entered the OLE (all pts group)
and (2) FAST4WARD CZP completers who entered OLE and did not receive MTX/
DMARDs (N48) (monotherapy subgroup).RESULTS: In both populations analyzed,
a rapid reduction in the number of days of household work days missed per month
was seen from feeder study baseline (BL, 7.4 and 11.1 mean days respectively) over
24wks of the feeder studies to OLE entry (3.5 and 4.1 mean days respectively) and
continued to decline over time, up to Week 268 (1.2 and 1.4 mean days respec-
tively). Increased participation in family/social/leisure activities was reported in
both populations, with a decrease in the number of days missed per month from
feeder study baseline (4.4 and 6.2 mean days, respectively), to entry to OLE, at a
mean of 1.3 and 1.1 days respectively for monotherapy pts; improvements contin-
ued over the 5 years to 0.4 and 0.2 days on average in the 2 populations respectively.
CONCLUSIONS: CZP treatment, in combination with MTX/DMARDs or as mono-
therapy, rapidly decreased the number of household work or social/family/leisure
days missed per month. These improvements were maintained up to 5 years with
open-label CZP following 24 wks double-blind CZP therapy.
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OBJECTIVES: Due to the global economic crisis, most of the actions of the Hungar-
ian government are focused on cost reductions, including in the health care sector.
According to the ownership structure’s changes (i.e., the state becoming the
owner), the most important thing is to create a well-monitored and centralized
hospital system. In addition to these changes, the government seeks to centralize
the procurement of pharmaceuticals and medical equipment at state-owned
hospitals.METHODS:We have prepared literature review and interviews with high
level hospital and political leaders to find how can we strengthen the regulation of
drug consumption at hospitals, which is at this time without strict controls.
RESULTS: Due to the specific objectives of the HunDRG system, which are focused
more on monitoring the number of DRG cases than tracking resources, there are no
incentives for hospitals to maintain strict inventories of their drugs. Except for
biological drugs, which use an itemized financing system, there is no pressure by
the government to monitor the medical costs at the unit level; as such, only hos-
pital data exists. Based on IMS data in 2011, the total hospital sector was valued at
approximately 100 billion HUF. Most of the hospitals do not have adequate com-
puter systems to monitor the patient-level data. CONCLUSIONS: In conclusion, the
so called unit-dose system could be a good solution to measure the drug consump-
tion at the patient level and to improve drug security (trial system). To sum up, it is
very important to gain more data regarding the Hungarian hospital system to be
able to create a sustainable, transparent, highly-regulated, and centralized public
health care system.
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OBJECTIVES: In France, the reimbursement decisions and price negotiations for
new drugs are highly influenced by the National Authority of Health (HAS) recom-
mendations communicated in the formal health technology assessment (HTA).
This study aimed to analyse past criterions and consider future possible require-
ments influencing future submissions.METHODS:A convenient internet literature
review was conducted to identify categories for value drivers in the evaluation of
the incremental medical benefit (ASMR) for a new product. An analysis of five
biological products reviewed 2006-2012 for rheumatology disorders was conducted
using these criterions. Based on the findings, exploratory interviews with two ex-
HAS members were performed to gain insight into future potential evidence
requirements. RESULTS: From the literature review three categories of evidence
were developed. Firstly ‘socioeconomics’, to include the French payers’ perspective
of burden and cost of illness. The second category was ‘clinical evidence’, evaluat-
ing the added therapeutic value for a target population, the clinical efficacy and
safety. The third category was ‘real world data’, to establish effectiveness and
long-term safety post-launch. From the analysis it was demonstrated that only
products targeting patients with an insufficient response to anti-TNFs were rec-
ommended a high -level II- ASMR. Only 2 of 14 phase III studies used an active
comparator in Phase III superiority studies. Open label extension studies were
commonly used to provide post-launch data. Findings of the interviews suggested
that in the future superiority verses current standard of care in France for a clear
target population would be the expectation for an ASMR  IV from the HAS.
CONCLUSIONS: These findings emphasise the need to integrate payer evidence
requirements into the clinical development strategy early on. Effort should be
directed towards the identification of a clear target population demonstrating su-
perior efficacy to standard of care.
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OBJECTIVES: To compare utilization of pain medications between osteoarthritis
(OA) patients initiating duloxetine and standard of care (SOC) after duloxetine’s
approval for OA. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult osteoarthritis patients (ICD-9-CM: 715.xx) initiating duloxetine
or SOC (celecoxib, gabapentin, pregabalin, or venlafaxine) between 11/2010 and
4/2011. Treatment initiation was defined as no pill coverage over 90 days prior, and
first dispense date was defined as index date. Included patients did not use opioids
in 90 days before index date. Propensity score matching was used to select patients
with similar baseline demographic and clinical characteristics for duloxetine and
SOC cohorts. Compliance to index medication was assessed via medication pos-
session ratio (MPR), proportion of days covered (PDC) and proportion discontinued
(a 60-day gap in medication access) for 6 months after index date. Opioids use
after index date was assessed and regression models were estimated to compare
opioid use between cohorts. RESULTS: A total of 1102 patients initiated duloxetine
and 4,302 patients initiated SOC. After matching, 1,021 patients were selected for
duloxetine (mean age: 63 years; female: 79%) and SOC (mean age: 64 years; female:
79%) cohorts, respectively. Duloxetine cohort had significantly higher MPR (0.80 vs.
0.74) and PDC (0.52 vs. 0.43), and were less likely to discontinue initiated medication
(55% vs. 68%) than SOC cohort (all p0.001). Duloxetine cohort was less likely to use
opioids after index date (49% vs. 56%, p0.002), and had fewer days on opioids
(mean: 18 vs. 22, p0.004) than SOC cohort. After adjusting for baseline character-
istics, duloxetine cohort initiated opioids later than SOC cohort (Hazard ratio: 0.85,
95% confidence interval: 0.75-0.97) and had fewer days on opioids (beta: -4.0,
p0.011). CONCLUSIONS: Patients with OA initiating duloxetine were associated
with better compliance to initiated medication and less likely to use opioids than
those initiating SOC.
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OBJECTIVES: To describe utilization patterns of duloxetine and celecoxib and sub-
sequent opioid use among patients with osteoarthritis (OA) after duloxetine’s ap-
proval for OA. METHODS: Pharmacy and medical claims from SDI Health were
analyzed for adult osteoarthritis patients (ICD-9-CM: 715.xx) who initiated dulox-
etine or celecoxib between 11/2010 and 4/2011. Initiation was defined as no pill
coverage in 90 days prior. Included patients had continuous enrollment in 6
months before and after the initiation and did not use opioid in 90 days before the
initiation. Propensity score matching was used to select patients with similar de-
mographic and clinical characteristics for duloxetine and celecoxib cohorts. Com-
pliance to index medication was assessed via medication possession ratio (MPR),
proportion of days covered (PDC), and proportion discontinued (no access for 60
days). Initiating dose and opioid use after index date was assessed. Cox propor-
tional hazard model was estimated to compare time to first opioid use. RESULTS:A
total of 1360 patients initiated duloxetine and 1,408 patients initiated celecoxib.
After matching, 784 patients were selected for duloxetine (mean age: 66, female:
78%) and celecoxib (mean age: 66; female: 76%) cohorts, respectively. 92.5% of
duloxetine cohort started on 60mg/day, the recommended dose, and 72.8% of
celecoxib cohort started on 200mg/day. Duloxetine cohort had higher MPR and
PDC and a lower proportion of discontinuation than celecoxib cohort (MPR: 0.81 vs.
0.70; PDC: 0.51 vs. 0.35; discontinuation: 57% vs. 78%. all p0.001). A lower propor-
tion of duloxetine cohort used opioids after index date (48.6% vs. 68.5%, p0.001),
and started on opioid later than celecoxib cohort (mean: 132 vs. 107, p0.001). After
controlling for baseline characteristics, duloxetine cohort initiated opioids later
than celecoxib cohort (Hazard ratio: 0.67, 95% confidence interval: 0.58-0.76).
CONCLUSIONS: OA patients initiating duloxetine had better compliance and a
lower likelihood of opioid utilization than those initiating celecoxib.
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OBJECTIVES: Opioids are commonly used to manage chronic pain, including os-
teoarthritis (OA). Duloxetine is approved for OA therapy, but no study has assessed
changes in utilization of opioid therapy following its approval. This study assessed
adherence and the change of opioid use between OA patients who initiated dulox-
etine versus celecoxib. METHODS: Employing administrative claims data, OA pa-
tients aged 18 years who initiated duloxetine or celecoxib between November
2010 and April 2011, and used opioids in 6 months before the initiation, were
identified. Initiation was defined as no access to the same medication over the prior
90 days, and the first dispense date of index medication was denoted as the “index
date”. Patients with80% days covered by index medication during follow-up were
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